RLYB

Rallybio Corporation (NASDAQ:RLYB) is a clinical-stage biotechnology company founded in 2018 and headquartered in New Haven, Connecticut. The company went public in July 2021 and focuses on discovering, developing, manufacturing, and delivering therapies for patients suffering from severe and rare diseases. Since its founding, Rallybio has concentrated its efforts on developing innovative treatments for conditions with significant unmet medical needs, particularly in areas where current therapeutic options are limited or nonexistent.